Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Jennifer Clarke (ucsf)
Headshot of Jennifer Clarke
Jennifer Clarke

Description

Summary

This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Lymphodepleting chemotherapy with cyclophosphamide and fludarabine before treatment with CAR T cells may make the CAR T cells more effective.

Official Title

Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma

Details

Keywords

EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma, Immunotherapy, CAR T Therapy, Cyclophosphamide, Fludarabine, E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection

Eligibility

Location

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist at University of California Health

  • Jennifer Clarke (ucsf)
    Jennifer L. Clarke, MD, MPH Professor of Clinical Neurology and Neurological Surgery Division of Neuro-Oncology Principal Investigator, Brain Tumor Research Center

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Hideho Okada, MD, PhD
ID
NCT06186401
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 20 study participants
Last Updated